secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0000950170-22-009659
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports Q1 net loss $26.0M; shares positive AML/NHL clinical data
------------------------------------------------------------------------

- Net loss $26.0M ($0.79/share); cash, equivalents & short-term investments $219.1M at 3/31/22, plus $215.5M net from April offering, pro forma >$400M.
- NKX101 Phase 1: 3 of 5 heavily pre-treated AML patients at higher dose achieved complete response; 2 of 3 CRs MRD-negative.
- NKX019 Phase 1: 5 of 6 NHL patients responded, 3 CR (including DLBCL and MCL); no CRS, GvHD, or ICANS observed in either study.
- Anticipates additional NKX101 and NKX019 dose-escalation data in H2 2022.
- Angela Thedinga appointed to Board of Directors in March 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022009659/0000950170-22-009659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022009659/nktx-20220512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer